drugset / Trial / NCT06249152

Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients

NCT06249152

Phase 2 Completed 36 enrolled Qlaris Bio, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Qlaris Phase 2 clinical study investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in combination with latanoprost in open-angle glaucoma (OAG) and/or ocular hypertension (OHT) patients.

Timeline

Start
2024-04-21
Primary completion
2024-12-20
Completion
2024-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject QLS-111 Unknown 0.015 % Other
Subject QLS-111 Unknown 0.03 % Other
Subject QLS-111 Unknown 0.075 % Other